le 30 avril 2021

As the quest to improve the drug development process continues, we are seeing the advent of new interventions on fast track approvals with post-approval commitments brought on by Regulator and Payer requirements.


As such, there is a need to improve our long term follow-up approach to ensure we are collecting accurate data and minimizing data loss.


Watch to learn how Syneos Health utilizes real world evidence as the bridge to seamlessly transition from clinical development to commercialization to enable data management, a simplified patient experience for better retention and significantly lower operational cost than traditional long term study approaches.


Scroll to Page Bottom Form 
Powered by Translations.com GlobalLink OneLink Software